This elevated MerTK expression is evidentin various cancer types, including acute leukemia (ALL or AML),, melanoma,, lung cancer, and prostate cancer. Inhibiting MerTKhas been shown to induce tumor cell death and activate the innateimmune response, suggesting its potential as a therapeutic target. This evidence concerns the gene MERTK and cancer.